Clinical Trial Update: Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase II study evaluating teriflunomide as adjunctive therapy to glatiramer acetate in multiple sclerosis; results completed with data posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• GLATIRAMER ACETATE (GLATIRAMER ACETATE)
• Teriflunomide (teriflunomide)

Snippet

Sponsor: Sanofi | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED | Results posted: 2012-11-02